Previous 10 | Next 10 |
Adamas has become much less exciting the last few years with sales of GOCOVRI slowing in its second year. They decided to give up on attempting to treat the walking speed in those with Multiple Sclerosis with GOCOVRI after lackluster results. Hope remains with a new CEO, Neil McFa...
Gainers: [[ADMS]] +13.2%. [[CTMX]] +5.6%. [[MSTR]] +4.9%. [[FARM]] +4.8%. [[NERV]] +4%.Losers: [[CATB]] -10.6%. [[PTVE]] -8%. [[MRVI]] -3.9%. [[ZI]] -3.8%. [[ICON]] -3.5%. For further details see: MSTR, ZI, ADMS and CATB among after-hours movers
Gainers: [[BBBY]] +17.7%. [[IMMP]] +15.8%. [[FHTX]] +7.6%. [[TLSA]] +6.8%. [[ADMS]] +6.8%.Losers: [[TTOO]] -20.3%. [[VIR]] -17.0%. [[GRTX]] -16.6%. [[AGIO]] -8.4%. [[WMG]] -7.7%. For further details see: BBBY, IMMP, TTOO and VIR among after-hours movers
Adamas Pharmaceuticals (ADMS) expects total revenue for Q4 to be $20.8M and $74.2M for FY 2020.Product sales of GOCOVRI is expected to be $19.8M for Q4, an increase of 21% from same quarter prior year and $71.2M for FY 2020.“I am proud of our team’s resilience, ab...
-- Total revenues expected to be $20.8 million for fourth quarter 2020 and $74.2 million for full year 2020 -- -- Product sales of GOCOVRI ® expected to be $19.8 million for fourth quarter 2020 and $71.2 million for full year 2020 -- -- Total prescriptio...
EMERYVILLE, Calif., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced that Neil F. McFarlane, Chief Executiv...
EMERYVILLE, Calif., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced the closing of the settlement of paten...
EMERYVILLE, Calif., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced that Neil F. McFarlane, the Company...
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...
Adamas Pharmaceuticals (ADMS) inks an agreement with Healthcare Royalty Partners amending its royalty-backed loan agreement. Key changes:Revised to provide for repayment from a royalty on OSMOLEX ER (amantadine) on the same terms as, and in addition to, the royalty for GOCOVRI ...
News, Short Squeeze, Breakout and More Instantly...
Adamas Pharmaceuticals Inc. Company Name:
ADMS Stock Symbol:
NASDAQ Market:
Adamas Pharmaceuticals Inc. Website:
Supernus Pharmaceuticals (NASDAQ: SUPN) recently announced that it's acquiring Adamas Pharmaceuticals (NASDAQ: ADMS) . In this Motley Fool Live video recorded on Oct. 13 , Motley Fool contributors Keith Speights and Brian Orelli discuss why Supernus' planned acq...
FinancialBuzz.com’s latest The Buzz Show: Featuring Our Corporate News Recap on “Adamas Pharmaceuticals, Inc. Announces Definitive Agreement to be Acquired by Supernus Pharmaceuticals, Inc” Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS) surged ove...
Supernus Pharmaceuticals Inc ( NASDAQ: SUPN ) recently announced that it had entered a definitive contract to acquire Adamas Pharmaceuticals ( NASDAQ: ADMS ). Supernus is to purchase this company a tender offer that was worth about $8.10 per share. The aggregate was roug...